- Andreas Lundh, PhD student1,
- Asbjørn Hróbjartsson, senior researcher1,
- Peter C Gøtzsche, professor and director1
- 1Nordic Cochrane Centre, Rigshospitalet, 2100 Copenhagen, Denmark
- al{at}cochrane.dk
Although the BMJ and Lancet provided Handel and colleagues access to information on reprint sales,1 the big US journals were unwilling to share this information. Our experience was similar when we investigated reprint sales.2
Much of the previous evidence in this field has been anecdotal, such as the infamous VIGOR trial of rofecoxib, where …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
PDF
Social bookmarking